Seminari di Ematologia Oncologica - Società Italiana di Ematologia

16 Seminari di Ematologia Oncologica
vival in patients with diffuse large B-cell lymphoma
treated with anthracycline-based chemotherapy with
and without rituximab. J Clin Oncol. 2008; 26: 447-454.
55. Evens Am, Sehn LH, Farinha P, Nelson BP, Raji A, Lu
Y et al. Hypoxia-inducible factor-1 {alpha} expression
predicts superior survival in patients with diffuse large
B-cell lymphoma treated with R-CHOP. J Clin Oncol.
2010; 28: 1017-1024.
56. Young KH, Leroy K, Møller MB, Colleoni GW, Sánchez-
Beato M, Kerbauy FR, et al. Structural profiles of TP53
gene mutations predict clinical outcome in diffuse large
B-cell lymphoma: an international collaborative study.
Blood. 2008; 112: 3088-3098.
57. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM,
Sehn LH, Farinha P, et al. MYC gene rearrangements
are associated with a poor prognosis in diffuse large
B-cell lymphoma patients treated with R-CHOP
chemotherapy. Blood. 2009; 114: 3533-3537.
58. Rossi D, Rasi S, Franceschetti S, Capello D, Castelli
A, De Paoli L, et al. Analysis of the host pharmacogenetic
background for prediction of outcome and toxicity
in diffuse large B-cell lymphoma treated with R-
CHOP21. Leukemia. 2009; 23: 1118-1126.
59. Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C,
Berger F, Rigal D, et al. Interleukin-10 gene promoter
polymorphisms influence the clinical outcome of diffuse
large B-cell lymphoma. Blood. 2004; 103: 3529-
3534.
60. Kube D, Hua TD, Von Bonin F, Schoof N, Zeynalova
S, Klöss M, et al. Effect of interleukin-10 gene polymorphisms
on clinical outcome of patients with
aggressive non-Hodgkin’s lymphoma: an exploratory
study. Clin Cancer Res. 2008; 14: 3777-3784.
61. Rossi D, Rasi S, Di Rocco A, Fabbri A, Forconi F,
Gloghini A, et al. The host genetic background of DNA
repair mechanisms is an independent predictor of survival
in diffuse large B-cell lymphoma. Blood. 2010; 117:
2405-13.
62. Hofmann WK, de Vos S, Tsukasaki K, Wachsman W,
Pinkus GS, Said JW, et al. Altered apoptosis pathways
in mantle cell lymphoma detected by oligonucleotide
microarray. Blood. 2001; 98: 787-794.
63. De Vos S, Krug U, Hofmann WK, Pinkus GS, Swerdlow
SH, Wachsman W, et al. Cell cycle alterations in the
blastoid variant of mantle cell lymphoma (MCL-BV) as
detected by gene expression profiling of mantle cell
lymphoma (MCL) and MCL-BV. Diagn Mol Pathol. 2003;
12: 35-43.
64. Morris SW, Kirstein MN, Valentine MB, Dittmer KG,
Shapiro DN, Saltman DL, et al. Fusion of a kinase gene,
ALK, to a nucleolar protein gene, NPM, in non-
Hodgkin’s lymphoma. Science. 1994; 263: 1281-1284.
65. Martinez-Delgado B. Peripheral T-cell lymphoma gene
expression profiles. Hematol Oncol. 2006; 24: 113-119.
66. Piccaluga PP, Agostinelli C, Zinzani PL, Baccarani M,
Dalla-Favera R, Pileri SA. Expression of platelet-derived
growth factor receptor alpha in peripheral T-cell lymphoma
not otherwise specified. Lancet Oncol. 2005;
6: 440.
67. Asano N, Suzuki R, Ohshima K, Kagami Y, Ishida F,
Yoshino T, et al. Linkage of expression of chemokine
receptors (CXCR3 and CCR4) and cytotoxic molecules
in peripheral T cell lymphoma, not otherwise specified
and ALK-negative anaplastic large cell lymphoma. Int
J Hematol. 2010; 91: 426-435.
68. Capello D, Martini M, Gloghini A, Cerri M, Rasi S,
Deambrogi C, et al. Molecular analysis of immunoglobulin
variable genes in human immunodeficiency virusrelated
non-Hodgkin’s lymphoma reveals implications
for disease pathogenesis and histogenesis.
Haematologica. 2008; 93: 1178-1185.
69. Carbone A, Gloghini A, Larocca LM, Capello D,
Pierconti F, Canzonieri V, et al. Expression profile of
MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines
novel histogenetic subsets of human immunodeficiency
virus-related lymphomas. Blood. 2001; 97: 744-751.